Message: | Even though immunotherapy has shown great potential in improving outcomes for patients with cancer, particularly through a combination of agents targeting immune inhibitory pathways, how to optimally combine the many new immunotherapy agents being developed remains a main question in cancer research. Creative Biolabs, who is focused on the discovery and development of antibody-based drugs, has successfully launched a well-established Magic™ “humanized” animal platform to offer humanized PD-1/OX40 dual immune checkpoint knock-in mice for our clients all over the world. https://www.creative-biolabs.com/drug-discovery/therapeutics/magic-humanized-pd-1-ox40-dual-immune-checkpoint-knock-in-mice.htm. |